Table 3. TEAEs following single administration of HLX01 or reference rituximab^a (phase 1b study) .

TEAEb	n (%)
	HLX01 (N=43)			Reference rituximab (N=43)
TEAE, treatment-emergent adverse event; ADR, adverse drug reaction; SAE, serious adverse event; WBC, white blood cell; a, The reference rituximab was sourced from China (MabThera®; rituximab-CN); b, Excluding infusion-related reactions; c, This includes events of chills, pyrexia and upper respiratory infection that started during the single dose phase; d, Where possible causal relationship to drug, device or administration.
Patients with ≥1 TEAEc	24 (55.8)			29 (67.4)
Patients with ADRd	14 (32.6)			21 (48.8)
Patients with significant TEAE	12 (27.9)			16 (37.2)
Patients with SAE	0			0
Patient death due to TEAE	0			0
Patient discontinuation due to TEAE	0			1 (2.3)
Grade	Grade 1	Grade 2	Grade 3	Grade 1	Grade 2	Grade 3
Patients with ≥1 TEAE	14 (32.6)	10 (23.3)	0	15 (34.9)	12 (28.0)	2 (4.7)
TEAEs ≥2 events by preferred term
Urinary tract infection	2 (4.7)	0	0	1 (2.3)	0	0
Upper respiratory tract infection	0	2 (4.7)	0	1 (2.3)	3 (7.0)	0
WBC decreased	1 (2.3)	4 (9.3)	0	1 (2.3)	1 (2.3)	1 (2.3)
Neutrophil count decreased	1 (2.3)	4 (9.3)	0	1 (2.3)	2 (4.7)	0
Blood immunoglobulin M decreased	0	0	0	2 (4.7)	0	0
Blood glucose increased	0	0	0	2 (4.7)	0	0
Arthralgia	1 (2.3)	2 (4.7)	0	0	0	0
Pruritus	3 (7.0)	0	0	3 (7.0)	0	0
Headache	0	0	0	2 (4.7)	0	0
Cough	2 (4.7)	0	0	0	2 (4.7)	0
Nausea	3 (7.0)	0	0	0	0	0
Rash	1 (2.3)	0	0	4 (9.3)	3 (7.0)	0
Dry mouth	1 (2.3)	0	0	2 (4.7)	0	0